Many exciting things happened in the field of dermatology in 2018. First of all, it was found that antibiotics, which were previously believed to be beneficial for acne, are actually advised against. Experts say that while antibiotics can help treat acne, strengthening antimicrobial resistance and death of new antibiotics support an argument for using less antibiotics in acne treatment. In another story related to antibiotics, it is emphasized to dermatologists to be sure about the diagnosis of acne. The similarities between acne and Pityrosporum folliculitis are large enough that antibiotics used to treat acne actually lead to a worsening condition if a patient has Pityrosporum folliculitis.
New treatments for melasma and hyperpigmentation were also discussed in 2018. A few of those discussed were, azelaic acid, tranexamic acid, glutathione, and B12. Experts say that the effectiveness of these new treatments are individually based. In other news, there are now updates in the guidelines of care and management of primary cutaneous melanoma by the American Academy of Dermatology. Overall, it was decided it’s best to consult physicians for guidance on treatment. This year there has also been a rise in frontal fibrosing alopecia, making the disorder go from rare to frequent. It is thought that the rise could be from facial moisturizers containing sunscreen.
The use of mobile apps for dermatology was called into question. It is estimated that only 20% of these apps are useful to patients. Experts are saying there is a need for a rating system to evaluate quality and utility of each app so consumers can be better informed. Treatment plans were discussed for those with acne scarring. There are new therapies now being used in addition to micro needling. A dermatologist discussed and advised on skin care, including diseased skin, eyelash extensions, and the use of cosmetic oils as cleansers. New treatments were also discussed for atopic dermatitis as well as hormonal acne.
One dermatologist that is well versed in these advances is Dr. Tim Ioannides. After graduating from the University of Miami School of Medicine, he founded Treasure Coast Dermatology, where he now practices dermatology. A member of the American Academy of Dermatology, Ioannides lends support to many local organizations and is a Voluntary Associate Professor at his alma mater.
Read This Article for additional information.
Phones have become very vital these days considering how they can expand the knowledge we have of our health. Every so often, new applications are created to bring you closer to determining your own diagnosis. Among all the medical applications that are available in app stores are ones that are geared toward dermatology. No longer will you have to scramble to set an appointment with your dermatologist to flood him or her with questions about what’s going on with your face. Instead, you can roll over from one side of your bed to the other, where your phone lays on the nightstand, pick up your phone and search through the medical application for symptoms that match the ones you are experiencing.
According to dermatologytimes.com, the following are the top 7 mobile applications when it comes to dermatology. They are given scores ranging from 11-15 which categorizes the app as “may be used for patient education with some reservations based on shortcomings for certain criteria” and 16 through 20 which classifies them as “valuable and adequate for patient education”:
- Doctor Derm was given a score of 19
- Eczema Doc is scored at 19
- Dermomedia received a score of 18
- Mollie’s Fund was awarded a score of 16
- Psoriasis Treatment Decision Aid is scored at 15
- Atopedia received a score of 14
- uDerm is scored at 11
If you’re still skeptical about seeking information about the state of your dermis via phone and you happen to be in the beautiful state of Florida, be relieved that experts such as Dr. Tim Ioannides still exist in their field. Dr. Ioannides has been serving the Treasure Coast in Florida for 15 plus years and he is board certified by the American Board of Dermatology.
Dr. Tim Ioannides is also a member of the American Academy of Dermatology, the American Society for Dermatologic Surgery, the American Society for Mohs Surgery, the American Medical Association, and the Florida Society of Dermatology and Dermatologic Surgery. He educates students of The University of Miami School of Medicine and Dr. Ioannides’s medical office serves the Stuart, Port St. Lucie, Fort Pierce, Vero Beach, and Sebastian areas. In comparison to Dr. Ioannides’s experience, your smartphone has quite a few years of catching up to do. See This Page for additional information.
Paragon Bioscience, led by chairman and CEO Jeff Aronin, is dedicated to improving medicine by supporting innovations in biomedical technologies. Paragon is an incubator and investor in the field of bioscience, which means they help fund and grow bioscience companies that they consider promising or innovative. Paragon currently has a diverse portfolio of cutting-edge biotech companies, including Castle Creek Pharmaceuticals, Harmony Biosciences, and Decade, a company that researches new types of therapy for people with Alzheimer’s.
Paragon’s approach is patient-driven, which means that they start by researching untreated diseases or conditions and then build bioscience companies to help treat these conditions. This business model serves Paragon well, as it guides their rational drug development programs and helps them speed along the approval process for promising and innovative treatments. Currently, Paragon has a pipeline of experimental drugs for the treatment of four different types of conditions, including central nervous system disorders, orphan dermatology, broader dermatology and pre-malignant oral lesions.
Jeff Aronin, the CEO of Paragon since 2010, has many years of experience leading biomedical companies and is an expert in business planning and development and brand marketing. In addition to serving as the CEO for Paragon, Mr. Aronin is also the non-executive chairman of multiple Paragon portfolio companies, including Castle Creek Pharmaceuticals and Harmony Biosciences. He has also served on the Board of Directors for Discover Financial Services since 2007.
Jeff Aronin’s skills and successes have made him one of the most innovative leaders in the bioscience sector, particularly in the field of biomedicine. His teams of scientists and executives have gotten 13 different Novel Drug Approvals from the FDA, which represent potentially life-saving medications for patients suffering from untreated medical conditions. Jeff Aronin also remains active in the field of philanthropy by supporting a variety of non-profit organizations dedicated to improving patient outcomes for different disease states. The non-profits that Mr. Aronin has supported include the Juvenile Diabetes Research Foundation, the JED Foundation for Depression, Liver Life Challenge and the Cystic Fibrosis Foundation, among other organizations.